Bristol-Myers Squibb Compnay

Lantheus Medical Imaging, Inc.

Other

Bristol-Myers Squibb Pharma Company

Douglas Dischino

David S Casebier

Heike S Radeke

Michael T Azure

Dasa Lipovsek

Simon P Robinson

Maria N Jure-Kunkel

Paul E Morin

Martin C Wright

Ajay Purohit

David Fabrizio

Jochem Gokemeijer

Daniel Cohen

David J Donnelly

Samuel J Bonacorsi, Jr

Virginie Lafont

Ralph Adam Smith

David K Leung

Samuel J Bonacorsi

David Donnelly

Provided herein are novelFn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

PD-L1 binding polypeptides for imaging

PET imaging with PD-L1 binding polypeptides

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Contrast agents for myocardial perfusion imaging

Provided herein are novel polypeptides comprising fibronectin type III tenth (Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.

Growing community of inventors

Middlefield, CT, United States of America

Douglas Dischino